Aurobindo Pharma inches up as its arm incorporates wholly owned subsidiary in Netherlands
Aurobindo Pharma inches up as its arm incorporates wholly owned subsidiary in Netherlands
May-29-2025 10:18 Hrs IST
Aurobindo Pharma is currently trading at Rs. 1151.35, up by 3.40 points or 0.30% from its previous closing of Rs. 1147.95 on the BSE.
The scrip opened at Rs. 1150.05 and has touched a high and low of Rs. 1160.10 and Rs. 1147.95 respectively. So far 9556 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1207.90 and Rs. 1144.30 respectively. The current market cap of the company is Rs. 66841.55 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.56% and 6.61% respectively.
Aurobindo Pharma’s wholly owned subsidiary (WOS) -- Curateq Biologics has incorporated a new wholly owned subsidiary in the Netherlands by the name of CuraTeQ Biologics B.V. The newly incorporated entity belongs to biopharma products industry. The object of incorporation of this WOS is to expand the biopharma products business in Europe.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
